Replies to post #355608 on Amarin Corp Plc (AMRN)

[rafunrafun]

But despite having so many other treatment alternatives, CVD is still the #1 killer and V reduces CVD rate by 25% on top of alternatives, which were allowed in REDUCE-IT.

[Meowza]

PFE needs to do a test run in

What the actual f---k are you talking about?

[bidmark]

“It won't kill a person until it's too late.”

- Yogi Berra

[ilovetech]

GG, quote: "Furthermore, CVD just has too many other cheaper and more widely adopted treatment alternatives than Vascepa."

Can you name "one?"

ILT

[CTW1]

Being a cardiac nurse practitioner, I don't agree. Everyday we start patients on a statin and if they don't tolerate one we start a different one. It is a primary prevention as Vascepa should be in my opinion. In my area we are just starting to see a few patients come through on Vascepa. I am hoping it becomes more wide spread for all cardiac patients as preventative

[couldbebetter]

Ggwpq, Good drugs do not sell themselves. Hopefully, KM has the
experience to insure a successful launch of Vazepa in Europe and
perhaps even get the company acquired in due time by BP. Thero
was a CPA with no BP experience behind him...He was the wrong guy
for the job. KM is a seasoned BP executive with experience in
launching new drugs in Europe. Europe is where the big money will
be made. Except, if a BP acquires AMRN they have the capability to
deliver much greater revenues and optimize uptake much faster.

Imagine if a BP acquired AMRN and decided that a generic version
would be the way to go in the US market. Could they rebrand or
relaunch the drug in some way to achieve greater sales in the US?
I don't know, but BP may have a solution; Thero's strategy failed.

[sts66]

Cheaper? Name one - PCSK9's cost 2x-3x/yr more than V and don't deliver anywhere close to the RRR V provides.

{CVD} won't kill a person until it's too late.

Yogi Berra impression?